Melanoma Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Melanoma Therapeutics | DelveInsight

DelveInsight's Melanoma Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Melanoma therapies in various stages of clinical development. The report provides insights into 150+ companies and 180+ pipeline drugs in the Melanoma pipeline landscape, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products.

Key takeaways from the Melanoma Clinical Trial Landscape Report

• DelveInsight's Melanoma pipeline report depicts a robust space with 150+ companies working to develop 180+ pipeline therapies for Melanoma treatment.
• Key Melanoma companies such as Amgen, Erasca, Inc., Innovent Biologics (Suzhou) Co. Ltd., Evaxion Biotech A/S, Phio Pharmaceuticals Inc., Biotroy Therapeutics, Pfizer, Adaptimmune, Servier and IDEAYA Biosciences, Inc., Rapa Therapeutics LLC, Merck Sharp & Dohme LLC, Idera Pharmaceuticals, Inc., Iovance Biotherapeutics, Inc., Celldex Therapeutics, and Immatics US, Inc.
• Promising Melanoma pipeline therapies in various stages of development include ABP-206, Naporafenib, IBI-363, EVX-01, PH-762, BT02, PF-08046031, ADP-600, Darovasertib, RAPA-201, V940, Tilsotolimod, Lifileucel plus Pembrolizumab, CDX-301, IOV-3001, IMA203, and others.

Request a sample and discover the recent advances in Melanoma treatment drugs https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Melanoma?

Melanoma is a malignant tumor arising from melanocytes. It is among the most common forms of cancer in young adults and typically presents as a new or changing pigmented (brown or black) skin lesion, although there are other presentations such as amelanotic or desmoplastic melanoma. When melanoma starts in the skin, the disease is called cutaneous melanoma. Melanoma is more aggressive than basal cell skin cancer or squamous cell skin cancer.
Melanoma of the skin can occur anywhere on the body. Unusual moles, exposure to natural sunlight or artificial sunlight over long periods of time, and family history can affect the risk of melanoma. Melanoma may also occur in mucous membranes.
Common signs and symptoms of melanoma include a new or unusual mole, blemish, or sore; a spot that looks different from others on the skin; changes in the size, shape, or color of a mole; itching, tenderness, or pain in a mole or lesion; bleeding, oozing, or crusting; and discoloration on the palms, soles, or mucous membranes.
Melanoma starts when melanocytes develop changes in their DNA. These changes can cause cancer cells to multiply rapidly and survive when healthy cells would normally die, resulting in an excessive accumulation of cells. Melanoma is commonly diagnosed through skin examination and biopsy, which also helps determine whether the cancer has spread and supports disease staging.
Treatment depends on the stage of the disease and may include surgery, chemotherapy, radiation therapy, immunotherapy, targeted therapy, and emerging approaches such as vaccine therapy.

Emerging Melanoma Drug Profiles

ABP-206: Amgen
ABP-206 is an investigational biologic being developed by Amgen for the treatment of Melanoma. It is designed as a biosimilar candidate to target immune checkpoint pathways involved in tumor growth. By modulating the immune system, ABP-206 aims to enhance anti-tumor responses in patients with advanced or metastatic Melanoma. The drug is currently in Phase III for the treatment of Melanoma.

IBI363: Innovent Biologics
IBI363 is the world's first PD-1/IL-2α-bias bispecific fusion protein independently developed by Innovent Biologics. It integrates two key functions: blockade of the PD-1/PD-L1 pathway and activation of the IL-2 signaling pathway. The IL-2 arm has been engineered to retain affinity for IL-2 Rα while reducing binding to IL-2Rβ and IL-2Rγ, thereby minimizing toxicity. The PD-1 binding arm enables simultaneous PD-1 blockage and selective delivery of IL-2. Currently, the drug is in Phase II stage of development for the treatment of Melanoma.

EVX-01: Evaxion Biotech A/S
EVX-01 is an investigational cancer immunotherapy developed by Evaxion Biotech A/S for the treatment of Melanoma. It is a personalized peptide-based vaccine designed using AI to identify tumor-specific neoantigens unique to each patient. By stimulating a targeted T-cell immune response, EVX-01 aims to improve tumor recognition and destruction. Currently, the drug is in Phase III for the treatment of Melanoma.

Learn more about the novel and emerging Melanoma pipeline therapies https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Melanoma Pipeline Report

• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Phase III, Phase II, Phase I, Preclinical, Discovery
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
• Key Melanoma Companies: Amgen, Erasca, Inc., Innovent Biologics (Suzhou) Co. Ltd., Evaxion Biotech A/S, Phio Pharmaceuticals Inc., Biotroy Therapeutics, Pfizer, Adaptimmune, Servier and IDEAYA Biosciences, Inc., Rapa Therapeutics LLC, Merck Sharp & Dohme LLC, Idera Pharmaceuticals, Inc., Iovance Biotherapeutics, Inc., Celldex Therapeutics, Immatics US, Inc.
• Key Melanoma Pipeline Therapies: ABP-206, Naporafenib, IBI-363, EVX-01, PH-762, BT02, PF-08046031, ADP-600, Darovasertib, RAPA-201, V940, Tilsotolimod, Lifileucel plus Pembrolizumab, CDX-301, IOV-3001, IMA203

Dive deep into rich insights for new drugs for Melanoma treatment, visit https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

1. Melanoma Pipeline Report Introduction
2. Melanoma Pipeline Report Executive Summary
3. Melanoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Melanoma Pipeline Therapeutics
6. Melanoma Pipeline: Late Stage Products (Phase III)
7. Melanoma Pipeline: Mid Stage Products (Phase II)
8. Melanoma Pipeline: Early Stage Products (Phase I)
9. Melanoma Pipeline: Preclinical and Discovery Stage Products
10. Melanoma Pipeline: Unknown Stage Products
11. Melanoma Pipeline Therapeutics Assessment
12. Inactive Products in the Melanoma Pipeline
13. Key Companies
14. Key Products in the Melanoma Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the Melanoma pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +1-469-945-7679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: DelveInsight

About DelveInsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, DelveInsight offers customized research solutions and insights to clients across the globe.

This release was published on openPR.